Breast Cancer Research and Treatment

, Volume 167, Issue 2, pp 603–604 | Cite as

A need for biology-driven personalized radiotherapy in breast cancer

  • Pelagia G. Tsoutsou
  • André-Dante Durham
  • Marie-Catherine Vozenin
Brief Report


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Jatoi I, Anderson WF, Jeong JH et al (2011) Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol 29:2301–2304CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Tsoutsou PG, Vozenin MC, Durham AD et al (2017) How could breast cancer molecular features contribute to locoregional treatment decision making? Crit Rev Oncol Hematol 110:43–48CrossRefPubMedGoogle Scholar
  3. 3.
    Kyndi M, Sørensen FB, Knudsen H, Danish Breast Cancer Cooperative Group et al (2008) Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish breast cancer cooperative group. J Clin Oncol 26:1419–1426CrossRefPubMedGoogle Scholar
  4. 4.
    Sjöström M, Lundstedt D, Hartman L et al. (2017) Response to radiotherapy after breast-conserving surgery in different breast cancer subtypes in the swedish breast cancer group 91 radiotherapy randomized clinical trial. J Clin Oncol Google Scholar
  5. 5.
    Duru N, Fan M, Candas D et al (2012) HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res 18:6634–6647CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Panoff JE, Hurley J, Takita C et al (2011) Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Res Treat 128(3):899–906CrossRefPubMedGoogle Scholar
  7. 7.
    Pietras RJ, Poen JC, Gallardo D et al (1999) Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59(6):1347–1355PubMedGoogle Scholar
  8. 8.
    Poortmans PM, Collette S, Kirkove C, EORTC Radiation Oncology and Breast Cancer Groups et al (2015) Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 373:317–327CrossRefPubMedGoogle Scholar
  9. 9.
    Punglia RS, Morrow M, Winer EP, Harris JR (2007) Local therapy and survival in breast cancer. N Engl J Med 356:2399–2405CrossRefPubMedGoogle Scholar
  10. 10.
    Karn T, Jiang T, Hatzis C et al. (2017) Association between genomic metrics and immune infiltration in triple-negative breast cancer. JAMA Oncol Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Radiation Oncology DepartmentHôpital NeuchâteloisLa Chaux-de-FondsSwitzerland
  2. 2.Division of Oncology, Radio-oncology DepartmentCentre Hospitalier Universitaire Vaudois (CHUV)LausanneSwitzerland
  3. 3.Radio-Oncology Research Laboratory of the CHUVLausanneSwitzerland

Personalised recommendations